ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1	crizotinib Sensitive: A1 - Approval crizotinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1	repotrectinib Sensitive: A1 - Approval repotrectinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2	lorlatinib Sensitive: A2 - Guideline lorlatinib Sensitive : A2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1	repotrectinib Sensitive: C1 - Off-label repotrectinib Sensitive : C1
ROS1 positive	Lung Cancer	ROS1 positive	Lung Cancer	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2	lorlatinib Sensitive: C2 – Inclusion Criteria lorlatinib Sensitive : C2
ROS1 positive	Solid Tumor	ROS1 positive	Solid Tumor	TQ-B3101 Sensitive: C2 – Inclusion Criteria TQ-B3101 Sensitive : C2	TQ-B3101 Sensitive: C2 – Inclusion Criteria TQ-B3101 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	AB-106 Sensitive: C2 – Inclusion Criteria AB-106 Sensitive : C2	AB-106 Sensitive: C2 – Inclusion Criteria AB-106 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	brigatinib Sensitive: C2 – Inclusion Criteria brigatinib Sensitive : C2	brigatinib Sensitive: C2 – Inclusion Criteria brigatinib Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	TQ-B3101 Sensitive: C2 – Inclusion Criteria TQ-B3101 Sensitive : C2	TQ-B3101 Sensitive: C2 – Inclusion Criteria TQ-B3101 Sensitive : C2
ROS1 positive	Mesothelioma	ROS1 positive	Mesothelioma	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2	APG-2449 Sensitive: C2 – Inclusion Criteria APG-2449 Sensitive : C2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	envonalkib Sensitive: C3 – Early Trials envonalkib Sensitive : C3	envonalkib Sensitive: C3 – Early Trials envonalkib Sensitive : C3
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3	ensartinib Sensitive: C3 – Early Trials ensartinib Sensitive : C3
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	ROS1 inhibitor Sensitive: C3 – Early Trials ROS1 inhibitor Sensitive : C3	ROS1 inhibitor Sensitive: C3 – Early Trials ROS1 inhibitor Sensitive : C3

ROS1 positive

Associations